NeoGenomics Buys Oncology Lab Genoptix

NeoGenomics Buys Oncology Lab Genoptix

by | Oct 26, 2018 2:43 pm | Laboratories, MRI & Dialysis | 0 comments

It’s been two years since NeoGenomics, Inc. (NASDAQ: NEO) announced an acquisition, but now the time clock has been reset. On October 23rd, the cancer-focused genetic testing company made public its purchase of Genoptix, Inc., a privately held clinical oncology laboratory specializing in hematology and solid tumor testing. Genoptix has well-established relationships with community oncology practices, a sales force and pathologists that are experienced in serving oncologists, and customized reports that are considered to be the gold standard among community oncologists. Oncology practices are an important, and under-penetrated, channel for promoting NeoGenomics’ capabilities in... Read More »

GE Healthcare Sells Clarient Lab Business

by | Oct 26, 2015 8:59 am | Laboratories, MRI & Dialysis | 0 comments

GE Healthcare (NYSE: GE)  sold Clarient, Inc. and its wholly owned subsidiary Clarient Diagnostic Services, Inc., which provides comprehensive cancer diagnostic testing to hospitals, physicians and the pharmaceutical industry. The acquirer was NeoGenomics, Inc. (NASDAQ: NEO), which,  together with its subsidiary, NeoGenomics Laboratories, Inc., operates a network of cancer-focused testing labs providing genetic and molecular services. The price, totaling $275,200,000, consists of $80 in cash, $110 million in preferred stock at $7.50 per share, and 15 million shares of NeoGenomics common stock ($85.2 million, based on the prior-day closing price of $5.68 per share). In effect, GE Healthcare... Read More »